Cholestatic liver diseases: new targets, new therapies.
Cholestatic liver diseases: new targets, new therapies.
复制标题
DOI:
10.1177/1756284818787400
复制
发表时间:
2018
影响因子:
4.2
通讯作者:
Levy C
中科院分区:
文献类型:
--
作者:
Santiago P;Scheinberg AR;Levy C
Cholestatic liver diseases result from gradual destruction of bile ducts, accumulation of bile acids and self-perpetuation of the inflammatory process leading to damage to cholangiocytes and hepatocytes. If left untreated, cholestasis will lead to fibrosis, biliary cirrhosis, and ultimately end-stage liver disease. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the two most common chronic cholestatic liver diseases affecting adults, and their etiologies remain puzzling. While treatment with ursodeoxycholic acid (UDCA) has significantly improved outcomes and prolonged transplant-free survival for patients with PBC, treatment options for UDCA nonresponders remain limited. Furthermore, there is no available medical therapy for PSC. With recent advances in molecular biochemistry specifically related to bile acid regulation and understanding of immunologic pathways, novel pharmacologic treatments have emerged. In this review, we discuss the standard of care and emphasize the various emerging treatments for PBC and PSC.
登录
查看更多内容
DOI:
10.1016/j.apsb.2015.01.004
发表时间:
2015-03
期刊:
Acta pharmaceutica Sinica. B
影响因子:
--
作者:
Ding L;Yang L;Wang Z;Huang W
通讯作者:
Huang W
影响因子:
9.1
作者:
Abarbanel, David N.;Seki, Scott M.;Cox, Kenneth L.
通讯作者:
Cox, Kenneth L.
影响因子:
2.9
作者:
Assis DN;Abdelghany O;Cai SY;Gossard AA;Eaton JE;Keach JC;Deng Y;Setchell KD;Ciarleglio M;Lindor KD;Boyer JL
通讯作者:
Boyer JL
影响因子:
13.5
作者:
BEUERS, U;SPENGLER, U;PAUMGARTNER, G
通讯作者:
PAUMGARTNER, G
影响因子:
9.8
作者:
Eaton, John E.;Silveira, Marina G.;Lindor, Keith D.
通讯作者:
Lindor, Keith D.